DiME Reveals Digital Measures For Treatment Of Atopic Dermatitis

Digital News

DiME reveals digital measures for treatment of atopic dermatitis

These resources offer a blueprint for future development of digital endpoints

The Digital Medicine Society (DiME) has released a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD), according to Pharma Phorum.

Nocturnal scratch aims to offer “new ways of measuring night-time scratching, using new digital tools to improve measurement of this distressing facet of AD.”

Kerry Capozza, Founder and Executive Director of Global Parents for Eczema Research explains, “There’s no easy solution, unless the eczema can be treated and brought under control”.

As it stands, no new medical product has been approved on the basis of a digital endpoint. DiMe has collaborated with founding partners Abbvie, Janssen, Novartis, Pfizer, and UCB, along with project collaborators Advancing Innovation in Dermatology, Almirall, Eli Lilly, GSK, Leo Pharma, and Sanofi. DiMe hopes nocturnal scratch will enact a shift in understanding, leading to industry alignment and acceptance.

Nocturnal scratch’s widespread implementation aims to establish a firmer digital groundwork for future clinical research, technology development, and reimbursement decisions in the dermatological field, therefore improving the lives of AD patients and caregivers.

The open-access resources were developed over a period of nine months, based on a mixedmethods study and comprehensive literature review, a series of workshops and focus groups with payers, as well as meeting with regulators.

It is anticipated that this will serve as a “blueprint for the broader development and deployment of digital endpoints in medical product development.”

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and triage patients with suspected hypertrophic cardiomyopathy (hcm).

Sooma receives FDA Breakthrough Device designation for depression therapy device

Finnish company Sooma medical has received breakthrough device designation by the FDA for its portable, at-home neuromodulation device to treat depression.

Elon Musk’s Neuralink rejected by FDA for human trials

The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which it proposed the initiation of human testing for its brain chip implants. The company has been working on brain implants that allow for a computer-brain interface, which could allegedly restore vision to the blind and help paralysed people to walk again.

AI Finds Liver Cancer Drug Candidate In Only 30 Days

A team of scientists have broken records with their new AI which has found a novel drug candidate for liver cancer in only 30 days

DrugBAN AI Expected To Reduce Costs And Speed Up Drug Discovery

A new AI has been developed to deliver medicines at a faster rate and lower cost

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Sooma receives FDA Breakthrough Device designation for depression therapy device

Elon Musk’s Neuralink rejected by FDA for human trials

AI Finds Liver Cancer Drug Candidate In Only 30 Days

DrugBAN AI Expected To Reduce Costs And Speed Up Drug Discovery

Pharmafocus

Categories

Social Footprints